A selection of recent successful placements and new projects globally. Focus in the 1st quarter of 2021 has been mainly on AI/Digital, Animal Health, Synthetic Biology, Vaccines, Diagnostics, CNS Diseases, Infectious Diseases, Immuno-oncology, Rare Diseases, Ophthalmology, Regenerative Medicine and Contract Manufacturing.
Author: Alison James
Coulter Partners was very pleased to partner recently with OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, to secure the appointment of Dr Allison Jeynes as non-executive Chair of the Board of Directors.
At their first HR Leadership Forum of the year in January, Coulter Partners launched the HR & Talent Leadership Pulse. This survey is designed for senior HR and Talent leaders globally in Life Sciences, Healthcare and Digital Health. Please take part and help us build a comprehensive picture… Through 2020 we saw incredible transformations across organisations, with HR and Talent professionals leading the way. To support this community in 2021, Coulter Partners has created the pulse survey which will continue to run throughout the year and monitor developments.
Coulter Partners was delighted to partner again recently with Optimapharm to secure the appointments of Walter Miller as Chief Finance Officer and Dr Charles Woler, M.D., Ph.D., as Non-Executive Director. Optimapharm is a contract research organization (CRO) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 27 countries across EMEA.
Coulter Partners recently talked to Dr James Field, Chief Executive Officer and Founder of LabGenius about digital disruption and talent in drug discovery. He told us, “We’ve developed a protein engineering platform that tightly integrates synthetic biology, machine learning, robotic automation and next generation sequencing. To achieve this, we’ve built a 50-strong team of data scientists, software engineers, automation engineers, drug discovery experts, molecular biologists, synthetic biologists… the list goes on…Our greatest challenge is one of organisational engineering: how to structure diverse teams of scientists and engineers to create value at the confluence of so many disparate technologies.”
New York, February 9, 2021 The Association of Executive Search and Leadership Consultants (AESC), the global standards-setting body for the executive search and leadership consulting profession, today announces 2021 officers and representatives to the AESC Council of Europe and Africa. Joe Coulter, newly announced AESC Europe and Africa Council Chair, commented: “The AESC Council of Europe and Africa plays an important role in ensuring AESC’s ongoing commitment to the highest standards in the executive search and leadership consulting profession across the region. I look forward to working with my fellow Council members to ensure we are creating the future of the profession on behalf of the clients we serve.”
Coulter Partners kicked off 2021 with the first HR Leadership Forum of the year. The Forum was set up in 2020 to bring together the HR community to discuss key topics and share experiences among peers. Topics included changes in talent behaviour, onboarding and retention, collaboration models in hybrid environments, management expectations and normalisation trends. The next forum will gather on 24 February…
The Association of Executive Search and Leadership Consultants (AESC), the standards-setting body for the executive search and leadership consulting profession worldwide, today announces 2021 officers and the appointments of three new Directors to its Global Board. Coulter Partners is delighted to announce Joe’s appointment to the Board, together with his promotion to Chair of the AESC Council of Europe and Africa.
A selection of recent successful placements and new projects globally. Focus in the 4th quarter of 2020 has been mainly on Rare diseases, Artificial Intelligence, Dental, Vaccines, P.O.C. Diagnostics, Gene therapy, Oncology, Cardiovascular, Women’s health, Neurology, Animal health and Venture teams.
Coulter Partners was delighted to partner with ObsEva SA (NASDAQ: OBSV / SIX: OBSN) to secure the appointment of Brian O’Callaghan as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will succeed Dr Ernest Loumaye and be proposed for election on ObsEva’s Board of Directors at the next company AGM. ObsEva SA is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health